DISRUPTIDE
Live / Applied — New application — not yet assigned to an examiner (as of 20 May 2026)
What this means for you
Not registered yet, but its 20 May 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99834893
- Mark type
- Stylized text
- Filed
- 20 May 2026
- Attorney of record
- Karen K. Won
Goods and services
- Class 001 — Chemicals: chemical preparations and reagents, namely, peptide sequences and peptide probes for use in drug discovery and development; AI-designed peptide probes for use in drug discovery and development; live-cell functional assays and drug screen assays involving engineered peptide probes, for research purposes; engineered peptide probes for live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; genetically-deliverable peptide sequences and peptide probes for preserving peptide conformation, minimizing steric interference, and enhancing peptide intracellular stability
- Class 042 — Scientific and technological services: Drug and drug target discovery services; Design, development, and engineering of peptide sequences and peptide probes for use in drug discovery and development; Medical scientific research, analysis, and testing, namely, using engineered peptide probes in live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; Using AI-designed peptide probes to conduct research, testing, and analysis of peptide-target pairs as molecular blueprints for developing small molecule inhibitors; Providing medical scientific information, advisory, and consultancy services in the fields of peptides, peptide-based drug discovery and development, and phenotypic drug screening
Owner
- Rime Therapeutics Inc., Montréal, QC, CA
Prosecution history
- 31 Jul 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 20 May 2026 — APPLICATION FILING RECEIPT MAILED
- 20 May 2026 — NEW APPLICATION ENTERED